Literature DB >> 3048803

An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.

N Jackson1, N R Ling, J Ball, E Bromidge, P D Nathan, I M Franklin.   

Abstract

Fresh bone marrow from 43 cases of myeloma and three cases of plasma cell leukaemia has been phenotyped both by indirect immune-rosetting and, on fixed cytospin preparations, by indirect immunofluorescence. Both clustered and unclustered B cell associated antibodies from the IIIrd International Workshop on Human Leucocyte Differentiation Antigens were used. The results confirm the lack of many pan-B antigens on the surface of myeloma plasma cells, i.e. CD19-23, 37, 39, w40. Strong surface reactivity is seen with CD38 antibodies and with one CD24 antibody (HB8). Weak reactions are sometimes obtained with CD9, 10 and 45R. On cytospin preparations CD37, 39 and w40 are sometimes weakly positive, and anti-rough endoplasmic reticulum antibodies are always strongly positive. Specific and surface-reacting antiplasma cell antibodies are still lacking.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3048803      PMCID: PMC1541577     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Ontogeny of B-lymphocyte differentiation induced by pokeweed mitogen.

Authors:  L Y Wu; A Blanco; M D Cooper; A R Lawton
Journal:  Clin Immunol Immunopathol       Date:  1976-03

2.  A simple and rapid method to distinguish between rosettes and non-specific aggregation of erythrocytes in the rosette assay for human T-lymphocytes.

Authors:  T Kalland
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

3.  Use of antibody-coated red cells for the sensitive detection of antigen and in rosette tests for cells bearing surface immunoglobulins.

Authors:  N R Ling; S Bishop
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

4.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

5.  Patterns of expression of human "Ia-like" antigens during the terminal stages of B cell development.

Authors:  J Halper; S M Fu; C Y Wang; R Winchester; H G Kunkel
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

6.  Antigens on human plasma cells identified by monoclonal antibodies.

Authors:  K C Anderson; E K Park; M P Bates; R C Leonard; R Hardy; S F Schlossman; L M Nadler
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

Review 7.  Surface markers on leukemia and lymphoma cells: recent advances.

Authors:  K A Foon; R W Schroff; R P Gale
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

8.  Fading of immunofluorescence during microscopy: a study of the phenomenon and its remedy.

Authors:  G D Johnson; R S Davidson; K C McNamee; G Russell; D Goodwin; E J Holborow
Journal:  J Immunol Methods       Date:  1982-12-17       Impact factor: 2.303

9.  Multiple myeloma: circulating lymphocytes that express plasma cell antigens.

Authors:  G J Ruiz-Argüelles; J A Katzmann; P R Greipp; N J Gonchoroff; J P Garton; R A Kyle
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

10.  Human b-cell differentiation. I. Analysis of immunoglobulin heavy chain switching using monoclonal anti-immunoglobulin M, G, and A antibodies and pokeweed mitogen-induced plasma cell differentiation.

Authors:  T Kuritani; M D Cooper
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  10 in total

1.  Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

Authors:  R Leo; M Boeker; D Peest; R Hein; R Bartl; J E Gessner; J Selbach; G Wacker; H Deicher
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

2.  Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry.

Authors:  H G Höffkes; G Schmidtke; M Uppenkamp; U Schmücker
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

Review 3.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

4.  Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis.

Authors:  Toru Takahashi; Tomofumi Miura; Junichiro Nakamura; Satoshi Yamada; Tsutomu Miura; Masahiko Yanagi; Yasunobu Matsuda; Hiroyuki Usuda; Iwao Emura; Koichi Tsuneyama; Xiao-Song He; M Eric Gershwin
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

5.  A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.

Authors:  A Vacca; R Di Stefano; A Frassanito; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

6.  Effect of interleukin-2 on the ex vivo growth of human myeloma cells.

Authors:  D Peest; I de Vries; R Hölscher; R Leo; H Deicher
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 7.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

8.  Expression of CD66a in multiple myeloma.

Authors:  Yukihiko Satoh; Toshiaki Hayashi; Tohru Takahashi; Fumio Itoh; Masaaki Adachi; Mikiko Fukui; Motomu Kuroki; Masahide Kuroki; Kohzoh Imai; Yuji Hinoda
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

Review 9.  Tumour biological aspects of CD24, a mucin-like adhesion molecule.

Authors:  G Kristiansen; M Sammar; P Altevogt
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

10.  Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2.

Authors:  N Jackson; J Lowe; J Ball; E Bromidge; N R Ling; S Larkins; M J Griffith; I M Franklin
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.